Darell Kumar, DO
Internal Medicine · Seattle, WANPI 1215335690
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Novo Nordisk at 55.9% of the total. Reporting peaked in 2022 at $278 and has fallen 52.6% since, to $132 in 2025.
Across 10 payments — averaging $60.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$335
- AstraZeneca$132
- Johnson & Johnson$39
- Amgen$34
- Welch Allyn$23
- Xeris Pharmaceuticals, Inc.$21
- plus $16 from 1 others
What the payments were for
- Food & beverage$57796%
- Other$234%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 3 | $335 |
| AstraZeneca | 1 | $132 |
| Johnson & Johnson | 1 | $39 |
| Amgen | 2 | $34 |
| Welch Allyn | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Novartis | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$600 in reported general payments places this provider in the 85th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 23 | $34,754 |
| EliquisApixaban | 11 | $17,650 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $2,375 |
| Atorvastatin Calcium | 119 | $1,141 |
| Gabapentin | 74 | $1,097 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $838 |
| Omeprazole | 41 | $830 |
| Amlodipine Besylate | 75 | $800 |
| Lisinopril | 89 | $712 |
| Levothyroxine Sodium | 62 | $667 |
| Metoprolol Succinate | 41 | $638 |
| ValacyclovirValacyclovir Hcl | 15 | $630 |
| Losartan Potassium | 70 | $626 |
| Ezetimibe | 11 | $612 |
| Duloxetine Hcl | 36 | $578 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Seattle
- Peter ShalitSeattle$1M
- Scott RamseySeattle$230K
- Michael CairnsSeattle$144K
- Peiqing QianSeattle$117K
- Kevin ChungSeattle$35K
- David DaleSeattle$35K
- Catherine BenzigerSeattle$13K
- Christopher DoddSeattle$12K
- Dedra BuchwaldSeattle$11K
- Thao NguyenSeattle$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.